Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.
IPO Year: 2014
Exchange: NASDAQ
Website: revance.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $16.00 → $9.00 | Buy → Neutral | Mizuho |
| 1/9/2024 | $30.00 → $8.00 | Buy → Neutral | Goldman |
| 8/16/2023 | $20.00 | Underperform → Neutral | Exane BNP Paribas |
| 10/11/2022 | $27.00 | Equal-Weight | Morgan Stanley |
| 9/22/2022 | $33.00 | Buy | Goldman |
| 10/26/2021 | $33.00 → $22.00 | Overweight | Barclays |
| 10/25/2021 | $17.00 | Overweight → Equal-Weight | Wells Fargo |
| 10/18/2021 | $45.00 → $25.00 | Buy | Needham |
| 10/18/2021 | $26.00 → $18.00 | Buy | HC Wainwright & Co. |
| 10/13/2021 | $35.00 → $26.00 | Buy | HC Wainwright & Co. |
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
10-Q - Revance Therapeutics, Inc. (0001479290) (Filer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
SCHEDULE 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:
Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:
Mizuho downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $9.00 from $16.00 previously
Goldman downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $8.00 from $30.00 previously
Exane BNP Paribas upgraded Revance Therapeutics from Underperform to Neutral and set a new price target of $20.00
Morgan Stanley initiated coverage of Revance Therapeutics with a rating of Equal-Weight and set a new price target of $27.00
Goldman initiated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $33.00
Barclays reiterated coverage of Revance Therapeutics with a rating of Overweight and set a new price target of $22.00 from $33.00 previously
Wells Fargo downgraded Revance Therapeutics from Overweight to Equal-Weight and set a new price target of $17.00
Needham reiterated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $25.00 from $45.00 previously
HC Wainwright & Co. reiterated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $18.00 from $26.00 previously
HC Wainwright & Co. reiterated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $26.00 from $35.00 previously
Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizard® (sunscreen), and StriVectin® (anti-aging) Opportunity for global commercialization capabilities with coverage of >10,000 medical professionals, mass retailers, specialty retailers, club retailers, and an ecommerce channel New product flow potential through internal product development and an integrated manufacturing operation Experienced leadership team that leverages the st
Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 or other locations and reference conference ID 218406, or from the webcast link in the investor relations section of the company's website at
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin Schilke is scheduled to present on Tuesday, June 4, 2024, at 11:20 am CT, in Chicago, Illinois. Goldman Sachs 45th Annual Global Healthcare Conference President and Chief Executive Officer Mark J. Foley is scheduled to present on Tuesday, June 11, 2024, at 8:00 am ET, in Miami, Florida. Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be availab
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 663066, or from the webcast link in the investor relations section of the company's website at www.
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units ("RSUs") to 29 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee's continued service relationship with Revance through the applicable vesting dates. The Compensation Committee of Revance's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with NASDAQ Listing Rule 5635(c)(4). About Revance Revance is a biotechnology company setting the new standard
Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance" or the "Company") today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. The gross proceeds from the public offering are expected to be $100.0 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about March 6, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXI
Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance" or the "Company") today announced a proposed underwritten public offering of $100 million of its common stock. In addition, the Company expects to grant the underwriter a 30-day option to purchase additional shares in an amount not to exceed 15% of the number of shares of common stock offered in the public offering. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY® and the RHA® Collection of dermal fillers, support the launch of DAXXIFY® into the therapeutics market, as well as for working capital, research and development and general corporate pur
Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 643827, or from the webcast link in the investor relations section of the com
Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences. Cowen 44th Annual Healthcare Conference Chief Executive Officer, Mark Foley and Chief Financial Officer, Tobin Schilke are scheduled to participate in a fireside chat on Tuesday, March 5, 2024, at 12:50p.m. EST, in Boston, Massachusetts. Barclays Global Healthcare Conference 2024 Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, March 12, 2024, at 9:30a.m. EST, in Miami, Florida. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at
Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York. Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Thursday, February 8, at 9:30a.m. EST. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About Revance Revance is a biotechnology company setting the new standard in heal
Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 or other locations and reference conference ID 218406, or from the webcast link in the investor relations section of the company's website at
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 663066, or from the webcast link in the investor relations section of the company's website at www.
Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 643827, or from the webcast link in the investor relations section of the com
Conference Call Scheduled for Wednesday, November 8, 2023 at 4:30 p.m. ET Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S. and Canadian callers, and reference conference ID 509643 or from the webcast link in the investor relations section of the company's website at: www.revance.com. A webc
Conference Call Scheduled for Tuesday, August 8, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (888) 330-3637 for U.S. and Canadian callers, and reference conference ID 5680588 or from the webcast link in the investor relations section of the company's website at: www.revance.com. A webcast
Conference Call Scheduled for Tuesday, May 9, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and reference conference ID: 7745325, or from the webcast link in the investor relations section of the company's website at:
Conference Call Scheduled for Tuesday, February 28, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 and reference conference ID: 1286316, or from the webcast link in the investor relations section of the company's website at: www.revance.com. A replay of the call w
Conference Call Scheduled for Tuesday, November 8, 2022 at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release third quarter 2022 financial results on Tuesday, November 8, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update. To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial
Conference Call Scheduled for Tuesday, August 9, 2022 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website
Conference Call Scheduled for Tuesday, May 10, 2022 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release first quarter financial results on Tuesday, May 10, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update. Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and referenc
HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $12 to $11.
Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $9 to $8.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag
Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday. Revance Therapeutics posted a GAAP loss of 54 cents per share, compared to market expectations for a loss of 63 cents per share. The company's quarterly sales came in at $51.936 million versus estimates of $56.634 million, according to data from Benzinga Pro. “We are very pleased to see the DAXXIFY strategy change continue to drive the desired momentum and market share gains. Notably, we saw a healthy uptick in volume both on a year-on-year basis, where aesthetic units sold increased by 105%, and on a sequential quarterly basis where aesthetic units sold increased by 7% despite traditional Q4 to Q
Piper Sandler analyst David Amsellem reiterates Revance Therapeutics (NASDAQ:RVNC) with a Overweight and lowers the price target from $20 to $11.
Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $9 to $8.
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $18 to $12.
With cash, cash equivalents, and short-term investments of $277.1 million as of March 31, 2024, and anticipated revenues and expenditures, management projects that the company will be funded to cash flow break-even and reach positive Adjusted EBITDA in 2025.
EDMONTON, AB, Nov. 17, 2022 /PRNewswire/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company. "We're excited to announce Aubrey Rankin's appointment to Nanostics' Board of Directors. Aubrey's vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®," said
- Q1 revenue for the RHA® Collection of dermal fillers of $11.6 million - HintMD's processing volume run-rate more than doubled to over $400 million from the prior quarter - Over 1,500 aesthetic accounts activated across products and services at quarter-end - Status of the U.S. Food and Drug Administration (FDA) pre-approval inspection - Conference call and webcast today at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Financial Highlights Revenue for the first quarter 2021 totaled $
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. Financial Highlights Revenue for the fourth quarter and full year ended December 31, 2020 was $11.1 million and $15.3 million compared to $0.1 million and $0.4 million for the same periods in 2019, respectively. The increase was primarily due to the commercial launch of the RHA® Collection of dermal fillers and the HintMD fintech platform. Revenue for the fourth quarter included $10.0 million of
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of accomplished biotech and pharmaceutical executive, Olivia C. Ware, and fintech and payments thought leader and entrepreneur, Carey O’Connor Kolaja, to its Board of Directors. The appointments will be made effective on March 1, 2021 for Ms. Kolaja and March 6, 2021, for Ms. Ware. “As we continue to grow and evolve our company strategy, it is critical that we expand the focus and expertise of our board. Olivia’s extensive background in drug portfolio and program management and Carey’s deep